# US 8,277,779 B2 · Compositions useful for reducing nephrotoxicity and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,277,779 B2
- Document ID: US8277779B2
- Status: Granted
- Kind: B2
- Application number: 12/641,708
- Filed: 2009-12-18
- Published: 2010-04-15
- Granted: 2012-10-02
- Earliest claimed: 2005-11-28
- Inventors: Vernon D. Rowe
- Web page: https://patentgrep.com/patent/US8277779B2

## CPC

- A61K 31/724: Cyclodextrins
- A61K 31/165: having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K 31/282: Platinum compounds
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/522: having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
- A61K 31/715: Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61P 13/12: of the kidneys
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 31/12: Antivirals
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 39/00: General protective or antinoxious agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides compositions and methods to reduce renal damage caused by nephrotoxic drugs. The invention provides compositions comprising an anionically substituted cyclodextrin, a nephrotoxic drug and a pharmaceutically acceptable carrier, where the cyclodextrin is present in an amount effective for substantially inhibiting the nephrotoxic effect of the drug.

## Claims

### Claim 1

A pharmaceutical composition comprising a substituted cyclodextrin of the formula:
cyclodextrin-[(O—R—Y)−(Me)+]n
where R is selected from the group consisting of straight chained or branched C1-10 alkyl, alkenyl or alkynyl;
Y is an anionic group selected from COO, SO3, SO4, PO3H or PO4;
Me is a pharmaceutically acceptable cation; and
n is a whole number greater than 1;
an iodinated contrast agent selected from iohexyl, ioversol, diatrizoate meglumine and ioxaglate; and
a pharmaceutically acceptable carrier;
wherein the molar ratio of agent:cyclodextrin is from 2:1 to 50:1.

### Claim 2 (depends on 1)

The composition of claim 1 wherein R is C1-4 alkyl selected from methyl, ethyl, propyl and butyl.

### Claim 3 (depends on 2)

The composition of claim 2 where R is butyl.

### Claim 4 (depends on 1)

The composition of claim 1 wherein Y is SO3.

### Claim 5 (depends on 4)

The composition of claim 4 wherein said cyclodextrin is selected from one or more of the group consisting of α, β and γ cyclodextrin.

### Claim 6 (depends on 1)

The composition of claim 1 wherein the agent is iohexyl.

### Claim 7 (depends on 6)

The composition of claim 6 wherein said cyclodextrin is β-cyclodextrin; (O—R—Y)−(Me)+ is —O—(CH2)4—SO3−Na+; and n is about 7.

### Claim 8

A method of reducing the nephrotoxicity of an iodinated contrast agent selected from iohexyl, ioversol, diatrizoate meglumine and ioxaglate comprising:
combining said agent with a substituted cyclodextrin of the formula:
cyclodextrin-[(O—R—Y)−(Me)+]n
where R is selected from the group consisting of straight chained or branched C1-10 alkyl, alkenyl or alkynyl;
Y is an anionic group selected from COO, SO3, SO4, PO3H or PO4;
Me is a pharmaceutically acceptable cation; and
n is a whole number greater than 1; and
a pharmaceutically acceptable carrier, wherein the molar ratio of agent:cyclodextrin is from 2:1 to 50:1; and
administering the resulting composition to a subject in need thereof.

### Claim 9 (depends on 8)

The method of claim 8 wherein the iodinated contrast agent is iohexyl.

### Claim 10 (depends on 8)

The method of claim 8 wherein said cyclodextrin is β-cyclodextrin, (O—R—Y)−(Me)+ is —O—(CH2)4—SO3−Na+, and n is about 7.
